Purdue Pharma LP filed for Chapter 11 bankruptcy Monday in a first step toward reorganizing as a new company designed to benefit plaintiffs in multidistrict litigation (MDL) and the American public in general. Read More
A study two years in the making concluded that the NIH's Bethesda, Md., campus needs a $1.3 billion upgrade to its buildings and facilities in order to succeed in what it calls "a highly competitive global biomedical research environment." Read More
Following data from a small phase IIa study showing its experimental Alzheimer's disease (AD) therapy, PTI-125, led to decreases in key biomarkers of neuroinflammation and neurodegeneration, Cassava Sciences Inc. (formerly Pain Therapeutics) has dosed the first two patients in a phase IIb study of the candidate. Read More
BEIJING – After a deal with Abbvie Inc. last year, Mumbai, India-based Lupin Ltd. inked another one, this time with German pharma Boehringer Ingelheim GmbH, to deepen its drug research efforts in gastrointestinal and lung cancers. Under the new agreement, the companies will explore the potential of a combination therapy using Lupin's MEK inhibitor compound, LNP-3794, and Boehringer Ingelheim's KRAS inhibitor. Read More
HONG KONG – In one of the latest combination efforts against cancer, Kahr Medical Ltd. is teaming up with Switzerland's Basel-based Roche Holding AG to study the use of the former's lead program, DSP-107, in combination with the latter's PD-L1-blocking checkpoint inhibitor, Tecentriq (atezolizumab), in patients with advanced non-small-cell lung carcinoma refractory to checkpoint inhibitors. Read More
Tarsius Pharma Ltd., of Tel-Aviv, Israel, was awarded a $2.6 million Horizon 2020 grant from the European Commission to begin clinical development of TRS, Tarsius' platform for treating autoimmune and inflammatory ocular diseases. Read More
Edigene Inc., of Beijing, said it completed an $11 million series pre-B2 financing round with series A lead investor IDG Capital and series pre-B lead investor Lilly Asia Ventures participating. Read More
When it comes to patent term extensions, a requested continued examination doesn't end until the U.S. Patent and Trademark Office (PTO) mails the notice of allowance, the U.S. Court of Appeals for the Federal Circuit said in a precedential ruling handed down Monday in Mayo Foundation for Medical Education and Research v. Iancu. Read More
DUBLIN – H. Lundbeck A/S is entering the crowded marketplace for antibody-based migraine therapies by acquiring Alder Biopharmaceuticals Inc. for up to $1.95 billion net of cash. Read More
